上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。
CGP-82996 (Synonyms: CINK4)
GP-82996 (CINK4) 是 CDK4/6 的药理学抑制剂。GP-82996 对 CDK4/cyclin D1、CDK6/cyclin D1 和 Cdk5/p35 的 IC50s 分别为 1.5、5.6 和 25 μM。GP-82996 诱导肿瘤细胞 U2OS 的凋亡 (apoptosis)。GP-82996可用于癌症研究。
CGP-82996 Chemical Structure
CAS No. : 359886-84-3
| 规格 |
|
是否有货 |
|
| 100 mg |
|
询价 |
|
| 250 mg |
|
询价 |
|
| 500 mg |
|
询价 |
|
* Please select Quantity before adding items.
| 生物活性 |
GP-82996 (CINK4) is a pharmacological inhibitor of CDK4/6. GP-82996 has IC50s of 1.5, 5.6 and 25 μM for CDK4/cyclin D1, CDK6/cyclin D1 and Cdk5/p35, respectively. GP-82996 induces the apoptosis of cancer cells U2OS. GP-82996 can be used in the research of cancer[1][2].
|
| IC50 & Target[1] |
|
Cdk4/cyclin D1
1.5 μM (IC50)
|
CDK6/cyclinD1
5.6 μM (IC50)
|
CDK5/p35
25 μM (IC50)
|
CDK2/cyclinA
>50 μM (IC50)
|
CDK1/cyclinB
>100 μM (IC50)
|
CDK2/cyclin E
>50 μM (IC50)
|
CDK4/cyclin D2
>50 μM (IC50)
|
Cdk6/cyclin D2
>50 μM (IC50)
|
V-abl
>10 μM (IC50)
|
c-met
>10 μM (IC50)
|
IGF-1R
>10 μM (IC50)
|
Insulin-R
>10 μM (IC50)
|
|
体外研究
(In Vitro) |
GP-82996 (5, 10 μM; 24 hours) induces G1 arrest and G0-G1/S ratio increase in U2OS (p16 negative) and MRC-5 (p16 positive) cells[1].
GP-82996 (5, 10 μM; 24 hours) reduces hyperphosphorylation of pRb, but has no changes in the levels of CDK4 in U2OS, MRC-5 cells[1].
GP-82996 (5, 10 μM; 48 hours) induces aooptosis in 83% of U2OS cells in concentration of 10μM[1].
GP-82996 (0.1-40 μM; 24,48, 72 hours) inhibits the cell proliferation of A549, H358, SKLU-1, H23, PC14 cells with IC50 values of 72 h are 4-7 μM[2].
GP-82996 (3, 5, 10 μM; 48 hours) induces G1 arrest in A549 and H23 cells[2].
GP-82996 ((1, 3, 5, 10 μM; 72 hours) enhances Paclitaxel sensitivity in KRAS mutation-bearing lung cancer cells (A549, SKLU-1, H23 cells) [2].
GP-82996 (10 μM; 72 hours) combined with Paclitaxel (3 nM; 72 hours) increases the apoptosis of A549 and H23 cells[2].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
|
体内研究
(In Vivo) |
GP-82996 (30 mg/kg, i.p. for 29 days) shows smaller final tumor volume compared with vehicle control in mouse xenograft models[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: |
19-21 g female BALB/c nu/nu mice xenograft model (HCT116 tumors volume=100 mm3)[1] |
| Dosage: |
30 mg/kg |
| Administration: |
i.p. every 12 hours for 29 days |
| Result: |
Showed smaller final tumor volume compared with vehicle control in mouse xenograft models. |
|
| 分子量 |
|
| Formula |
|
| CAS 号 |
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere.
|
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis.
|
| 溶解性数据 |
In Vivo:
-
1.
5% DMSO, 0.05% Tween 80, and 95% physiologic saline
|
| 参考文献 |
-
[1]. Soni R, et al. Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. J Natl Cancer Inst. 2001 Mar 21;93(6):436-46.
[2]. Zhang XH, et al. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS. Cancer Biol Ther. 2013;14(7):597-605.
|
所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务
